[go: up one dir, main page]

EE200200506A - 5-alkylpyrido [2,3-d] pyrimidines as tyrosine kinase inhibitors - Google Patents

5-alkylpyrido [2,3-d] pyrimidines as tyrosine kinase inhibitors

Info

Publication number
EE200200506A
EE200200506A EEP200200506A EEP200200506A EE200200506A EE 200200506 A EE200200506 A EE 200200506A EE P200200506 A EEP200200506 A EE P200200506A EE P200200506 A EEP200200506 A EE P200200506A EE 200200506 A EE200200506 A EE 200200506A
Authority
EE
Estonia
Prior art keywords
alkylpyrido
pyrimidines
tyrosine kinase
kinase inhibitors
inhibitors
Prior art date
Application number
EEP200200506A
Other languages
Estonian (et)
Inventor
Laurence Toogood Peter
John Booth Richard
Myra Dobrusin Ellen
Norman Vanderwel Scott
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200200506A publication Critical patent/EE200200506A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200200506A 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d] pyrimidines as tyrosine kinase inhibitors EE200200506A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
EE200200506A true EE200200506A (en) 2004-02-16

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200506A EE200200506A (en) 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d] pyrimidines as tyrosine kinase inhibitors

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
WO2002059083A2 (en) 2000-10-23 2002-08-01 Smithkline Beecham Corporation Novel compounds
DE60206363T2 (en) * 2001-02-12 2006-07-06 F. Hoffmann-La Roche Ag 6-SUBSTITUTED PYRIDOPYRIMIDINES
CA2438294C (en) 2001-02-26 2008-10-21 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
WO2003000270A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidones and uses thereof
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
JP4603268B2 (en) 2002-04-19 2010-12-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New compounds
US7585866B2 (en) 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
WO2004033446A1 (en) 2002-10-09 2004-04-22 Danter Wayne R Protein tyrosine kinase inhibitors
ATE433967T1 (en) * 2003-01-17 2009-07-15 Warner Lambert Co 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
NZ544609A (en) * 2003-07-11 2008-07-31 Warner Lambert Co Isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
JP5010917B2 (en) * 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド c-Kit Regulator and Method of Use
EP1685131B1 (en) 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
JP2008510770A (en) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel pteridinone as a PLK inhibitor
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
CA2594860A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
PE20100737A1 (en) 2005-03-25 2010-11-27 Glaxo Group Ltd NEW COMPOUNDS
SG160438A1 (en) 2005-03-25 2010-04-29 Glaxo Group Ltd Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5- d]pyrimidin-2(1h)-one derivatives
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
UY29439A1 (en) 2005-03-25 2006-10-02 Glaxo Group Ltd NEW COMPOUNDS
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
WO2007044813A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
JP5480503B2 (en) * 2005-10-07 2014-04-23 エクセリクシス， インク． PI3Kα pyridopyrimidinone type inhibitor
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PL2074122T3 (en) 2006-09-15 2011-10-31 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
JP2010506902A (en) * 2006-10-16 2010-03-04 ジーピーシー・バイオテック・インコーポレーテッド Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
US8138181B2 (en) * 2007-04-03 2012-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
SI2168966T1 (en) 2007-06-15 2017-03-31 Msd K.K. Bicycloaniline derivative
EP3098223A1 (en) 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
ATE531372T1 (en) * 2008-04-07 2011-11-15 Amgen Inc GEM-DISUBSTITUTED AND SPIROCYCLIC AMINOPYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
UY32153A (en) 2008-09-30 2011-04-29 Exelixis Inc PY13KA (ALFA) AND MTOR PYRIDOMIDINONE INHIBITORS
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
MX2012004157A (en) * 2009-10-09 2012-08-03 Afraxis Inc 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders.
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
AR080151A1 (en) 2010-02-09 2012-03-14 Exelixis Inc METHODS TO TREAT CANCER USING PI 3K PYRIDOPIRIMIDINONE INHIBITORS AND MTOR IN COMBINATION WITH AUTOPHAGIA INHIBITORS
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US8987267B2 (en) 2010-08-05 2015-03-24 Temple University—Of the Commonwealth System of Higher Education 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
PT2646448T (en) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Macrocyclic kinase inhibitors
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
KR102027598B1 (en) * 2011-05-17 2019-10-01 프린시피아 바이오파마, 인코퍼레이티드 Tyrosine kinase inhibitors
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
EP2817308B1 (en) * 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
EP2958916B1 (en) * 2013-02-21 2018-09-12 Pfizer Inc Solid forms of a selective cdk4/6 inhibitor
JP2016525532A (en) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of myelodysplastic syndrome
JP6631616B2 (en) * 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 2-Amino-pyrido [2,3-d] pyrimidin-7 (8H) -one derivatives as CDK inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
PE20190475A1 (en) 2016-08-15 2019-04-04 Pfizer CDK2 / 4/6 INHIBITORS
US11192890B2 (en) * 2017-03-03 2021-12-07 Auckland Uniservices Limited FGFR kinase inhibitors and pharmaceutical uses
EP3752491A4 (en) 2018-02-15 2021-12-01 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
CN113166148B (en) * 2018-12-07 2024-04-12 杭州英创医药科技有限公司 Heterocyclic compounds as CDK-HDAC dual pathway inhibitors
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
EP4065578A1 (en) 2019-11-26 2022-10-05 Theravance Biopharma R&D IP, LLC Fused pyrimidine pyridinone compounds as jak inhibitors
WO2022188755A1 (en) * 2021-03-08 2022-09-15 暨南大学 Pyridopyrimidine-based compound and application thereof
KR20240021239A (en) * 2021-06-09 2024-02-16 티와이케이 메디슨즈, 인코포레이티드 Compounds used as CDK kinase inhibitors and their uses
JP2025531320A (en) * 2022-09-16 2025-09-19 イースト チャイナ ノーマル ユニバーシティ Pyridonopyrimidine derivatives as RSK inhibitors and their applications
WO2024099403A1 (en) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
BR9807305A (en) * 1997-02-05 2000-05-02 Warner Lambert Co Pyrido [2,3-d] pyrimidines and 4-aminopyrimidines as inhibitors of cell proliferation.
KR20010043829A (en) * 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Bicyclic Pyrimidines and Bicyclic 3,4-Dihydropyrimidines as Inhibitors of Cellular Proliferation

Also Published As

Publication number Publication date
BR0109056A (en) 2003-06-03
CA2401368A1 (en) 2001-09-27
PE20011177A1 (en) 2001-11-23
DZ3308A1 (en) 2001-09-27
NZ520962A (en) 2003-09-26
NO20024235L (en) 2002-11-05
CZ20022929A3 (en) 2003-02-12
EP1268476A1 (en) 2003-01-02
BG107161A (en) 2003-06-30
WO2001070741A1 (en) 2001-09-27
HN2001000040A (en) 2001-09-06
SK12472002A3 (en) 2003-04-01
AU2001233028A1 (en) 2001-10-03
EA200200802A1 (en) 2003-02-27
OA12227A (en) 2004-03-18
GT200100037A (en) 2002-03-04
CN1422268A (en) 2003-06-04
MA26881A1 (en) 2004-12-20
SV2001000338A (en) 2001-11-30
HRP20020798A2 (en) 2004-02-29
PA8513201A1 (en) 2003-06-30
AP2002002643A0 (en) 2002-12-31
AR034119A1 (en) 2004-02-04
CO5280200A1 (en) 2003-05-30
MXPA02008535A (en) 2002-12-13
KR20020075805A (en) 2002-10-05
ZA200207110B (en) 2003-12-04
JP2003528101A (en) 2003-09-24
IL151480A0 (en) 2003-04-10
IS6524A (en) 2002-08-23
TNSN01036A1 (en) 2005-11-10
YU66502A (en) 2005-09-19
HUP0300136A2 (en) 2003-05-28
PL358271A1 (en) 2004-08-09
NO20024235D0 (en) 2002-09-05
CR6736A (en) 2004-03-10

Similar Documents

Publication Publication Date Title
EE200200506A (en) 5-alkylpyrido [2,3-d] pyrimidines as tyrosine kinase inhibitors
EE200200405A (en) Pyrido [2,3-d] pyrimidine-2,7-diamines as kinase inhibitors
NO20021820D0 (en) Tyrosine kinase inhibitors
EP1161433A4 (en) TYROSINE KINASE INHIBITORS
AP2003002781A0 (en) Quinolinone derivatives as tyrosine kinase inhibitors
ATE257157T1 (en) PYRROLO(2,3-D)PYRIMIDINE COMPOUNDS AS PROTEIN KINASE INHIBITORS
PL373300A1 (en) Novel tyrosine kinase inhibitors
EE200200140A (en) Pteridinones as kinase inhibitors
AU2000240570A1 (en) Pyrrolopyrimidines as tyrosine kinase inhibitors
DK1416935T3 (en) 4-Amino-6-phenyl-pyrrolo [2,3-d] pyrimidine derivatives
EP1259236A4 (en) TYROSINE KINASE INHIBITORS
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002253350A1 (en) 4-aminosulfonylquinazolines and -quinolines as tyrosine kinase inhibitors
DE50103649D1 (en) 2-aminoalkyl-THIENO [2,3-D] PYRIMIDINES
DK1226136T3 (en) tyrosine kinase
AU2002326466A1 (en) Tyrosine kinase inhibitors
AU2002304001A1 (en) Tyrosine kinase inhibitors
AU2002327342A1 (en) Tyrosine kinase inhibitors
AU2002322568A1 (en) Tyrosine kinase inhibitors
AU2002326865A1 (en) Tyrosine kinase inhibitors
AU2002326760A1 (en) Tyrosine kinase inhibitors
AU2002326758A1 (en) Tyrosine kinase inhibitors